Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Action immédiate contre l’arthrite réunit 21 organisations, plus de 100 000 patients, des chercheurs, des cliniciens et des défenseurs de la cause afin de transformer la recherche sur l’arthrite et...
-
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
-
TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...
-
Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.
-
Cleveland CLASH integrates EPHI’s LSLRCC into public resources, expanding access to cost and planning tools for lead service line replacement.
-
Access Recognized by Inc. in its 2026 List of the Fastest Growing Private Companies in the Northeast
PEABODY, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Access, a leading global integrated information management solutions provider, is pleased to announce today that it has been recognized by Inc. in...
-
Gigamon is recognized as the leading vendor in the deep observability market with 51 percent market share in 2025 by 650 Group.
-
New research from Momentive Software finds growth path visibility and technology efficiency are critical to workforce stability in mission-driven sector.
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Micron Biomedical makes the Most Innovative Companies List in recognition of clinical, financial and other progress toward needle-free vaccines and drugs.